EICHORCondition: Colon Cancer · Oxaliplatin-induced Peripheral Neuropathy · Sponsor: AC Camargo Cancer Center
Interested? Contact the study team ↓
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
The primary objective of this randomized clinical trial is to assess whether the use of surgical gloves during treatment can prevent the occurrence of oxaliplatin-induced peripheral neuropathy.
This description comes directly from the study's public registry record.
Virgilio Souza Silva, Medical Doctor, PhD · +55 (11) 2189-5000 · virss2013@gmail.com
Éverton Germano Melo, Medical Doctor · +55 (43) 3379-2600 · evertongermanomelo@gmail.com
There is no obligation to join — the study team can answer your questions about taking part.
Always discuss trial participation with your own doctor first.
Inclusion Criteria: * Patients aged 18 years or older who have provided written informed consent. * Colon adenocarcinoma with high-risk stage III (pT4pN2) or stage IV. * Oxaliplatin-based treatment in the context of localized or metastatic disease. * Eastern Cooperative Oncology Group (ECOG) performance status of 0-1. Exclusion Criteria: * Pre-existing neuropathy. * Uncontrolled diabetes. * known glove allergies. * Prior treatment with paclitaxel, docetaxel or oxaliplatin.
Reproduced word-for-word from the public registry record — the study team can answer questions about it.
| A.C. Camargo Cancer Center | São Paulo, São Paulo, Brazil | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07285356